These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30107489)

  • 1. Reduction in mortality from implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy patients is dependent on the presence of left ventricular scar.
    Gutman SJ; Costello BT; Papapostolou S; Voskoboinik A; Iles L; Ja J; Hare JL; Ellims A; Kistler PM; Marwick TH; Taylor AJ
    Eur Heart J; 2019 Feb; 40(6):542-550. PubMed ID: 30107489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between mortality and implantable cardioverter-defibrillators by aetiology of heart failure: a propensity-matched analysis of the WARCEF trial.
    Lee TC; Qian M; Mu L; Di Tullio MR; Graham S; Mann DL; Nakanishi K; Teerlink JR; Lip GYH; Freudenberger RS; Sacco RL; Mohr JP; Labovitz AJ; Ponikowski P; Lok DJ; Estol C; Anker SD; Pullicino PM; Buchsbaum R; Levin B; Thompson JLP; Homma S; Ye S;
    ESC Heart Fail; 2019 Apr; 6(2):297-307. PubMed ID: 30816013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mean entropy predicts implantable cardioverter-defibrillator therapy using cardiac magnetic resonance texture analysis of scar heterogeneity.
    Gould J; Porter B; Claridge S; Chen Z; Sieniewicz BJ; Sidhu BS; Niederer S; Bishop MJ; Murgatroyd F; Ganeshan B; Carr-White G; Razavi R; Chiribiri A; Rinaldi CA
    Heart Rhythm; 2019 Aug; 16(8):1242-1250. PubMed ID: 30849532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can QRS scoring predict left ventricular scar and clinical outcomes?
    Rosengarten JA; Scott PA; Chiu OK; Shambrook JS; Curzen NP; Morgan JM
    Europace; 2013 Jul; 15(7):1034-41. PubMed ID: 23493411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adding the implantable cardioverter-defibrillator to cardiac resynchronization therapy is associated with improved long-term survival in ischaemic, but not in non-ischaemic cardiomyopathy.
    Witt CT; Kronborg MB; Nohr EA; Mortensen PT; Gerdes C; Jensen HK; Nielsen JC
    Europace; 2016 Mar; 18(3):413-9. PubMed ID: 26378089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and study protocol for the BRITISH randomized trial (Using cardiovascular magnetic resonance identified scar as the benchmark risk indication tool for implantable cardioverter defibrillators in patients with nonischemic cardiomyopathy and severe systolic heart failure).
    Flett A; Cebula A; Nicholas Z; Adam R; Ewings S; Prasad S; Cleland JG; Eminton Z; Curzen N
    Am Heart J; 2023 Dec; 266():149-158. PubMed ID: 37777041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myocardial scar characteristics based on cardiac magnetic resonance imaging is associated with ventricular tachyarrhythmia in patients with ischemic cardiomyopathy.
    Demirel F; Adiyaman A; Timmer JR; Dambrink JH; Kok M; Boeve WJ; Elvan A
    Int J Cardiol; 2014 Dec; 177(2):392-9. PubMed ID: 25440471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left ventricular scar burden specifies the potential for ventricular arrhythmogenesis: an LGE-CMR study.
    Scott PA; Rosengarten JA; Murday DC; Peebles CR; Harden SP; Curzen NP; Morgan JM
    J Cardiovasc Electrophysiol; 2013 Apr; 24(4):430-6. PubMed ID: 23210601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myocardial scar burden predicts survival benefit with implantable cardioverter defibrillator implantation in patients with severe ischaemic cardiomyopathy: influence of gender.
    Kwon DH; Hachamovitch R; Adeniyi A; Nutter B; Popovic ZB; Wilkoff BL; Desai MY; Flamm SD; Marwick T
    Heart; 2014 Feb; 100(3):206-13. PubMed ID: 24186562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival and arrhythmic risk among ischemic and non-ischemic heart failure patients with prophylactic implantable cardioverter defibrillator only therapy: A propensity score-matched analysis.
    Briongos-Figuero S; Estévez A; Luisa Pérez M; Martínez-Ferrer JB; García E; Viñolas X; Arenal Á; Alzueta J; Basterra N; Rodríguez A; Lozano I; Muñoz-Aguilera R
    Int J Cardiol; 2019 Jan; 274():163-169. PubMed ID: 30206014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New York Heart Association functional class and implantable cardioverter-defibrillator in non-ischaemic heart failure with reduced ejection fraction: Extended follow-up of the DANISH trial.
    Karacan MN; Doi SN; Yafasova A; Thune JJ; Nielsen JC; Haarbo J; Bruun NE; Gustafsson F; Eiskjær H; Hassager C; Svendsen JH; Høfsten DE; Pehrson S; Køber L; Butt JH
    Eur J Heart Fail; 2024 Jun; 26(6):1423-1431. PubMed ID: 38733253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implantable Cardioverter Defibrillators for Primary Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials.
    Stavrakis S; Asad Z; Reynolds D
    J Cardiovasc Electrophysiol; 2017 Jun; 28(6):659-665. PubMed ID: 28316104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implantable cardioverter-defibrillator therapy among patients with non-ischaemic vs. ischaemic cardiomyopathy for primary prevention of sudden cardiac death.
    Amara N; Boveda S; Defaye P; Klug D; Treguer F; Amet D; Perier MC; Gras D; Algalarrondo V; Bouzeman A; Piot O; Deharo JC; Fauchier L; Babuty D; Bordachar P; Sadoul N; Marijon E; Leclercq C;
    Europace; 2018 Jan; 20(1):65-72. PubMed ID: 28082419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of mortality benefit based on periodic repolarisation dynamics in patients undergoing prophylactic implantation of a defibrillator: a prospective, controlled, multicentre cohort study.
    Bauer A; Klemm M; Rizas KD; Hamm W; von Stülpnagel L; Dommasch M; Steger A; Lubinski A; Flevari P; Harden M; Friede T; Kääb S; Merkely B; Sticherling C; Willems R; Huikuri H; Malik M; Schmidt G; Zabel M;
    Lancet; 2019 Oct; 394(10206):1344-1351. PubMed ID: 31488371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implantable cardioverter defibrillators for primary prevention in patients with nonischemic cardiomyopathy: A systematic review and meta-analysis.
    Akel T; Lafferty J
    Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28129469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left ventricular function improvement after prophylactic implantable cardioverter-defibrillator implantation in patients with non-ischaemic dilated cardiomyopathy.
    Grimm W; Timmesfeld N; Efimova E
    Europace; 2013 Nov; 15(11):1594-600. PubMed ID: 23639855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Implantation of Primary Prevention Implantable Cardioverter Defibrillators for Patients with Newly Diagnosed Severe Nonischemic Cardiomyopathy.
    Voskoboinik A; Bloom J; Taylor A; Mariani J
    Pacing Clin Electrophysiol; 2016 Sep; 39(9):992-8. PubMed ID: 27343008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implantable cardioverter defibrillator therapy in patients with ischemic or non-ischemic cardiomyopathy and nonsustained ventricular tachycardia.
    Evonich RF; Maheshwari A; Gardiner JC; Khasnis A; Kantipudi S; Ip JH; Grimes D; Hayter G; Thakur RK
    J Interv Card Electrophysiol; 2004 Aug; 11(1):59-65. PubMed ID: 15273456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [ECG score to predict ICD therapies in patients with nonischemic cardiomyopathy and primary prophylactic CRT-D].
    Grett M; Christ M; Röing Gen Nölke JP; Trappe HJ
    Herzschrittmacherther Elektrophysiol; 2017 Mar; 28(1):48-53. PubMed ID: 28204917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.